Monoclonal antibodies are created using a technique known as hybridoma technology. This process involves the fusion of an antibody-producing B-cell with a myeloma (cancer) cell, resulting in a hybrid cell line, or hybridoma, capable of producing large quantities of identical antibodies. These antibodies are specifically designed to bind to certain antigens, making them highly specific.
